The DART Study- Daratumumab Treatment in ITP

Summary

A multicenter clinical, open-label total dose-escalating phase II study with safety run-in to explore the clinical activity, total dosage, and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after corticosteroids and at least one second-line therapy including rituximab and/or TPO-RA.

Timeline

Start

2021-01-21

Primary completion

2024-04

Completion

2024-12

Publications

• Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjonnfjord E, Munthe LA, Drivet E, Kared H, Sorvoll IH, Ahlen MT, Mahevas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W. Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv. 2026 Jan 13;10(1):143-154. doi: 10.1182/bloodadvances.2025017279.

Drugs

Indications